Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers HARP MRK
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides U.S. Regulatory Update on Gefapixant
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK MRNA
Merck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO® (Fluralaner) for Use in Dogs
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces First-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Acquire Caraway Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Jefferies London Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the UBS BioPharma Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Third-Quarter 2023 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.